Summary of Use during Lactation

Topical tazarotene has not been studied during breastfeeding. Some experts feel it should not be used on a large surface area (perhaps greater than 20% of body surface area) while nursing because of possible absorption.[1] Others recommend that it not be used during breastfeeding because of its suspected mutagenic properties.[2] If tazarotene is used, ensure that the infant's skin does not come into direct contact with the areas of maternal skin that have been treated and the infant does not ingest the product from the mother's skin.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Phototherapy, Tretinoin

References

1.

Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol 2024;91:651-68. [PubMed: 38280680]

2.

Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol 2019;5:141-50. [PMC free article: PMC6637092] [PubMed: 31360745]

Substance Name

Tazarotene

CAS Registry Number

118292-40-3

Drug Class

Breast Feeding

Lactation

Milk, Human

Dermatologic Agents

Keratolytic Agents